Madison Muller
@g0ingmad
Health reporter for @business in New York | Email: [email protected] | find me on signal
Grocery shopping after making my trip to Iceland last week my entire personality
The definitive story of how Hims found itself in the crosshairs of Big pharma, MAHA, short sellers, regulators, meme-stock investors—and those trying to lose weight. @g0ingmad @devinleonard in the latest @BW bloomberg.com/news/features/…
Teamed up again with my colleague,@g0ingmad, this time to chronicle the career and controversies of Hims & Hers CEO Andrew Dudum in the latest @BW. Gift-linked. Enjoy! bloomberg.com/news/features/…
US ice cream makers are planning to eliminate a number of artificial colors from their products by 2028 bloomberg.com/news/articles/…
Chinese drugmakers have come a long way from their copycat days to challenge Western dominance on innovation. Our latest story visualizes this stunning advance, with data from @NorstellaCo with @hongjinshan and @spepechen: bloomberg.com/news/features/…
This month’s Businessweek cover story is out, and it’s me and Lily Meier on whether, after decades of declining sales and failed turnarounds, Gap might actually, finally be making a comeback. (Except, oops, the tariffs!) Gift link: bloomberg.com/news/features/…
Hims & Hers Health won’t back down from selling cheap weight-loss shots, its CEO said after Novo Nordisk abruptly ended its distribution partnership bloomberg.com/news/articles/…
NEW: Hims won’t back down from selling copycat weight-loss shots after Novo Nordisk abruptly ended its distribution partnership. “There’s just no way in hell we’re going to cave on that," CEO @AndrewDudum told @business. More here from me + @devinleonard: bloomberg.com/news/articles/…
Scenes from @AmDiabetesAssn in Chicago, where the booths this year are bigger, brighter and more high-tech than ever
Lilly's top oncology execs: If a cancer program needs a mid-stage trial, its too mid for Lilly. My look at Lilly's cancer pipeline revamp and its unconventional strategy: endpoints.news/phase-3-or-bus…
New: Hims is cutting more than 4% of its workforce. “While not easy, this step reflects our commitment to invest in the areas that will define our future,” a spokesperson told me. More here for @business⬇️ bloomberg.com/news/articles/…
US health officials are terminating a contract with Moderna worth up to $766 million to develop vaccines for bird flu. Story w/ @g0ingmad bloomberg.com/news/articles/…
New: The ouster of Lars Fruergaard Jorgensen — only the fifth CEO in Novo’s century-long history — marks a turning point in the race to dominate the pharmaceutical industry’s hottest market. More from me and @naomikresge here: ⬇️ bloomberg.com/news/features/…
“If they’re available at the pharmacy, people assume they’re overseen by the FDA, but unfortunately, in the case of these unapproved drugs, they aren’t.” Read the latest from @annaedney ⬇️⬇️ bloomberg.com/news/articles/…?
“This is the first event where I haven’t fought with the audience,” @calleymeans tells @maxonwifi 🤣
NEW: Empower Pharmacy, which calls itself the US’ “largest and most advanced” compounding pharmacy has used poor-quality ingredients, skirted regulations and pushed out or sued employees who raised concerns, an Endpoints News investigation found. endpts.com/pharmacy-empow…
Extremely humbled to be named a @NIHCMfoundation Investigative & General reporting finalist for our reporting on Ozempictown, USA! @devinleonard @tanaz115
Congratulations to the Investigative & General Reporting finalists for the 31st Annual #NIHCMAwards in Journalism! We are delighted to recognize their outstanding work. Read the webpage for more: bit.ly/IGRFinalists